Astellas Pharma Inc. ALPMY Stock
Astellas Pharma Inc. Price Chart
Astellas Pharma Inc. ALPMY Financial and Trading Overview
| Astellas Pharma Inc. stock price | 13.47 USD |
| Previous Close | 13.48 USD |
| Open | 13.52 USD |
| Bid | 13.47 USD x 20000 |
| Ask | 13.49 USD x 460000 |
| Day's Range | 13.47 - 13.52 USD |
| 52 Week Range | 9.11 - 17.35 USD |
| Volume | 13.06K USD |
| Avg. Volume | 174.75K USD |
| Market Cap | 24.13B USD |
| Beta (5Y Monthly) | 0.071 |
| PE Ratio (TTM) | 13.336634 |
| EPS (TTM) | 1 USD |
| Forward Dividend & Yield | 0.5 (3.67%) |
| Ex-Dividend Date | March 31, 2026 |
| 1y Target Est | 17.4 USD |
ALPMY Valuation Measures
| Enterprise Value | 310.28B USD |
| Trailing P/E | 13.336634 |
| Forward P/E | 29.933334 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.0112803355 |
| Price/Book (mrq) | 2.1286628 |
| Enterprise Value/Revenue | 0.145 |
| Enterprise Value/EBITDA | 0.54 |
Trading Information
Astellas Pharma Inc. Stock Price History
| Beta (5Y Monthly) | 0.071 |
| 52-Week Change | 44.77% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 17.35 USD |
| 52 Week Low | 9.11 USD |
| 50-Day Moving Average | 14.49 USD |
| 200-Day Moving Average | 13.58 USD |
ALPMY Share Statistics
| Avg. Volume (3 month) | 174.75K USD |
| Avg. Daily Volume (10-Days) | 243.77K USD |
| Shares Outstanding | 1.79B |
| Float | 1.79B |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.027% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 78 |
| Trailing Annual Dividend Yield | 578.63% |
| 5 Year Average Dividend Yield | 356.00% |
| Payout Ratio | 0.4706 |
| Last Split Factor | 125:100 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2026 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | March 31, 2027 |
Profitability
| Profit Margin | 13.62% |
| Operating Margin (ttm) | 16.50% |
| Gross Margin | 80.90% |
| EBITDA Margin | 26.86% |
Management Effectiveness
| Return on Assets (ttm) | 6.87% |
| Return on Equity (ttm) | 17.43% |
Income Statement
| Revenue (ttm) | 2.14T USD |
| Revenue Per Share (ttm) | 1194.37 USD |
| Quarterly Revenue Growth (yoy) | 20.69% |
| Gross Profit (ttm) | 1.73T USD |
| EBITDA | 574.65B USD |
| Net Income Avi to Common (ttm) | 291.53B USD |
| Diluted EPS (ttm) | 1.01 |
| Quarterly Earnings Growth (yoy) | -3.89% |
Balance Sheet
| Total Cash (mrq) | 281.61B USD |
| Total Cash Per Share (mrq) | 157.19 USD |
| Total Debt (mrq) | 565.95B USD |
| Total Debt/Equity (mrq) | 30.91 USD |
| Current Ratio (mrq) | 1.167 |
| Book Value Per Share (mrq) | 6.327916 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 560.19B USD |
| Levered Free Cash Flow (ttm) | 388.72B USD |
Profile of Astellas Pharma Inc.
| Country | United States |
| State | N/A |
| City | Chuo |
| Address | 2-5-1, Nihonbashi-Honcho |
| ZIP | 103-8411 |
| Phone | 81 3 3244 3000 |
| Website | https://www.astellas.com |
| Industry | Drug Manufacturers - General |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Q&A For Astellas Pharma Inc. Stock
What is a current ALPMY stock price?
Astellas Pharma Inc. ALPMY stock price today per share is 13.47 USD.
How to purchase Astellas Pharma Inc. stock?
You can buy ALPMY shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Astellas Pharma Inc.?
The stock symbol or ticker of Astellas Pharma Inc. is ALPMY.
Which industry does the Astellas Pharma Inc. company belong to?
The Astellas Pharma Inc. industry is Drug Manufacturers - General.
How many shares does Astellas Pharma Inc. have in circulation?
The max supply of Astellas Pharma Inc. shares is 1.79B.
What is Astellas Pharma Inc. Price to Earnings Ratio (PE Ratio)?
Astellas Pharma Inc. PE Ratio is 13.47000000 now.
What was Astellas Pharma Inc. earnings per share over the trailing 12 months (TTM)?
Astellas Pharma Inc. EPS is 1 USD over the trailing 12 months.
Which sector does the Astellas Pharma Inc. company belong to?
The Astellas Pharma Inc. sector is Healthcare.